FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
Name and Address of Reporting Person* Dexter Susan				So	2. Issuer Name and Ticker or Trading Symbol Sonnet BioTherapeutics Holdings, Inc. [SONN]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below) Chief Technical Officer						
(Last) (First) (Middle) 100 OVERLOOK CENTER, SUITE 102					3. Date of Earliest Transaction (Month/Day/Year) 12/15/2021									Chie	1 Technical	Officer			
PRINCETON,, NJ 08540				4. I	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui							quir	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Exe (any		ate, if	Code (Instr. 8)		(4	(A) or Disposed of (Instr. 3, 4 and 5)		d of (of (D) Benefici Reported		unt of Securities cially Owned Following ed Transaction(s)		Form:		7. Nature of Indirect Beneficial
				(M	onth/Day/	Year)	Code	e	VA	Amoun	(A) or (D)			(Instr. 3 a	,		Direct or Indi (I) (Instr.	indirect (Instr. 4)	
Common	Stock		12/15/2021				A			3,104	A	<u>(1)</u>	1	126,572	,		D		
			Table		ivative Sec			t	the for	m dis	plays a f, or Be	a cur enefic	ren cially	tly valid	OMB con	spond unle trol numbe			
1. Title of Derivative Security (Instr. 3) Price of Derivative Security		3. Transaction Date (Month/Day/	Year) Execution	med n Date, if	4. Transaction Code Year) (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7 A U S (I	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ow For De Sec Dir or I		Ownersh (Instr. 4)	
					Code	v	(А) (Г]	Date Exercis		Expiration Date	on T	itle	Amount or Number of Shares					
Repor	ting O	wners																	

		Relationships						
Reporting Owner Name / Address		Director	10% Owner	Officer	Other			
Dexter Susan 100 OVERLOOK CENT PRINCETON,, NJ 08540	· · · · · · · · · · · · · · · · · · ·			Chief Technical Officer				

Signatures

/s/ John Harry Cross III, power of attorney	04/08/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On December 15, 2021, the Reporting Person was granted 63,104 restricted stock units, which will be settled in shares of common stock, par value \$0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.